pharmaceuticals

Pfizer

Pfizer Stock Buyback Plan Just Too Large to Ignore — It Is on Viagra

A Pfizer Inc. (NYSE: PFE) press release on Thursday evening was honestly given the wrong title by the company's investor relations department. The new release titled "Pfizer Declares 26-Cent Fourth-Quarter ...
Read Full Story »
135093244

Companies That Benefit as Sexually Transmitted Disease Cases Keep Growing

Although it is a subject many investors would like to avoid, for obvious reasons, the growth in the number of sexually transmitted diseases (or STDs, as they are called) is ...
Read Full Story »
Pills

3 Irish Specialty Pharmaceutical Stocks to Buy After Tax Inversion Implosion

For now, while the benefit for American corporations to buy or merge and move overseas may be over, as evidenced by AbbVie cancelling its merger with Shire Pharmaceutical, that doesn't ...
Read Full Story »
Merger

NewLink Scores Major Partners With Roche’s Genentech

NewLink Genetics Corp. (NASDAQ: NLNK) announced that it has entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group, for the development of NLG919, NewLink's ...
Read Full Story »
Ebola Virus

Ebola Stocks Move in Different Directions

Recently we have seen a surge in Ebola-related stocks across the board, but Friday trading brings a mixed view for this group. Allied Healthcare Products Inc. (NASDAQ: AHPI) in Friday ...
Read Full Story »
Ebola Virus

Ebola Stocks on the Move

Investors fan the flames of Ebola fears in the market, enabling these biotech companies to profit from these fears. Ultimately these fears and some hopes of potential contracts or increased ...
Read Full Story »
Ebola Virus

Ebola Fears Driving Ebola Stock Winners

Fears of Ebola have plagued the United States since late September, and some biotech companies have capitalized on this fear. These fears and some hopes of potential contracts or increased ...
Read Full Story »
Pills

Diplomat Turns Bunt Pricing Into Homerun for IPO Buyers

Diplomat Pharmacy Inc. (NYSE: DPLO) priced 13.3 million initial public offering (IPO) shares at $13 on Thursday, below the expected range of $14 to $16. When the stock began trading ...
Read Full Story »
fda_logo

Alcobra Loses Focus in ADHD Trial for FDA Approval

Cognitive disorders, specifically Attention Deficit Hyperactivity Disorder (ADHD), are prevalent within the United States and affect 5% of children. Around half of these children will continue to have ADHD as ...
Read Full Story »
biotech

Makers of the 10 Top-Selling Cancer Drugs Catch the Eye of Analyst

One sad thing for almost every citizen in the United States is that at one point almost all of us will either have cancer or have a friend or relative ...
Read Full Story »
Biotechnology word cloud

Biotech Company FibroGen Files for IPO

FibroGen Inc. filed its S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No terms were given for the offering, but they filed ...
Read Full Story »
biotech

3 Likely Biotech Buyout Candidates

The pharmaceutical business is a difficult one, because patent expiration and competition are always omnipresent factors. Obviously major companies like to keep large research and development projects moving at full ...
Read Full Story »
Biotechnology word cloud

5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition. In the United States and the European Union, it is easier to ...
Read Full Story »
biotech

DBV Technologies Files for IPO, Sort Of

DBV Technologies has filed an F-1 form with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO). At least it is an IPO in the United ...
Read Full Story »
upgrade

Canaccord Genuity Doubles Price Target for Medivation

Medivation Inc. (NASDAQ: MDVN) received an upgrade from Canaccord Genuity on the heels of it continually increasing its 52-week high over the past month. This upgrade comes on analyst John ...
Read Full Story »